Pseudotyped GFP rSARS-CoV-2 Spike (COV-PS02)

Product Overview
SARS-CoV-2 Pseudovirus are used to test the ability of serum, antibodies, and drugs to neutralize the infectivity of SARS-CoV-2 spike protein. Pseudovirus display antigenically correct spike protein pseudotyped on replication-incompetent virus particles that contain a heterologous lentiviral (HIV) core. Pseudovirus are capable of a single round of infection and carry a genome that expresses either a GFP reporter gene upon infection. Pseudovirus are produced in HEK293T cells using three separate plasmids, encoding the spike protein, a lentiviral gag polyprotein, and a reporter gene. Pseudovirus are created using a second-generation lentiviral system with components that are highly unlikely to recombine to produce a fully infectious virus (requiring 3 separate recombination events to do so). However, lentiviruses are capable of genomic integration and Pseudovirus are derived from biological materials so should be handled with caution within a BSL2 or enhanced BSL2 laboratory environment.
Application Notes
We recommended to use 10-30 uL pseudotyped virus per 10E+04 293T cells for in vitro assay. Due to differences in cell status,the best infection conditions and MOI should be determined by the end user.The virus can be diluted with cell culture medium if needed.
1 mL
Store at -80°C. Multiple freeze/thaw cycles not recommended.
When using the virus, transfer the virus from the -80 ° C refrigerator and melt it in an ice bath.
Frozen on dry ice
Biosafety Level:    BSL-2
It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.


Have you cited COV-PS02 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds


Authors: Liu, Pei; Liu, Hongbo; Sun, Qi; Liang, Hao; Li, Chunmei; Deng, Xiaobing; Liu, Ying; Lai, Luhua

SARS-CoV-2 3C like protease is the main protease of SARS-CoV-2 and has been considered as one of the key targets for drug discovery against COVID-19. We identified several N-substituted isatin compounds as potent SARS-CoV-2 3C-like protease inhibitors. The three most potent compounds inhibit SARS-CoV-2 3C-like protease with IC50's of 45 nM, 47 nM and 53 nM, respectively. Our study indicates that N-substituted isatin compounds have the potential to be developed as broad-spectrum anti-coronavirus drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.

Abrupt Deterioration of COVID-19 Patients and Spreading of SARS COV-2 Virions in the Lungs


Authors: Filipovic, N.; Saveljic, I.; Hamada, K.; Tsuda, A.

A unique feature of COVID-19 interstitial pneumonia is an abrupt progression to respiratory failure. Our calculation shows that this abrupt deteriorate may be caused by a sudden shift in the spread of virus-laden bioaerosols through the airways to many different regions of the lungs from the initial site of infection.

Bayati A, Kumar R, Francis V, et al. SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis[J]. Journal of Biological Chemistry, 2021: 100306.

Have you cited COV-PS02 in a publication? Let us know and earn a reward for your research.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket